KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deferred Tax Liability (2022 - 2025)

Recursion Pharmaceuticals' Non-Current Deferred Tax Liability history spans 4 years, with the latest figure at $23.3 million for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 74.63% year-over-year to $23.3 million; the TTM value through Dec 2025 reached $23.3 million, down 74.63%, while the annual FY2025 figure was $23.3 million, 74.63% down from the prior year.
  • Non-Current Deferred Tax Liability reached $23.3 million in Q4 2025 per RXRX's latest filing, roughly flat from $23.3 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $91.7 million in Q4 2024 to a low of $168000.0 in Q3 2024.
  • Average Non-Current Deferred Tax Liability over 4 years is $20.0 million, with a median of $16.9 million recorded in 2023.
  • Peak YoY movement for Non-Current Deferred Tax Liability: crashed 91.3% in 2024, then soared 13776.19% in 2025.
  • A 4-year view of Non-Current Deferred Tax Liability shows it stood at $11.9 million in 2022, then surged by 41.77% to $16.9 million in 2023, then soared by 441.91% to $91.7 million in 2024, then tumbled by 74.63% to $23.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Non-Current Deferred Tax Liability are $23.3 million (Q4 2025), $23.3 million (Q3 2025), and $23.8 million (Q2 2025).